Table 1.
Clinical variables of patients at entry to the study
| OME (n= 78) | RAB (n= 78) | |
|---|---|---|
| Age (years) | 69.4 (20.3, 80.4) | 67.9 (21.2, 81.9) |
| Sex (%) | ||
| Male | 55 (70.5%) | 58 (74.4%) |
| Female | 23 (29.5%) | 20 (25.6%) |
| Locations of ulcer (%) | ||
| Stomach | 42 (53.8%) | 39 (50%) |
| Duodenum | 32 (41.0%) | 37 (47.4%) |
| Oesophagus | 4 (5.2%) | 2 (2.6%) |
| Endoscopic findings (%) | ||
| Spurting | 3 (3.8%) | 0 |
| Oozing | 28 (35.9%) | 33 (42.3%) |
| NBVV | 24 (30.8%) | 18 (23.1%) |
| Clot | 23 (29.5%) | 26 (33.3%) |
| Gastric contents (%) | ||
| Blood | 25 (32.1%) | 20 (25.6%) |
| Coffee grounds | 33 (42.3%) | 35 (44.9%) |
| Clear | 20 (25.6%) | 23 (29.5%) |
| Shock (%) | 21 (26.9%) | 16 (20.5%) |
| Medical comorbidity (%) | 50 (64.1%) | 51 (65.4%) |
| Ulcer size (cm) | 1.06 (0.4, 2.0) | 1.12 (0.5, 2.1) |
| Helicobacter pylori infection (%) | 48 (61.5%) | 51 (65.4%) |
| Haemoglobin (g l−1) | 9.81 (9.32, 10.48) | 10.31 (9.83, 10.85) |
| Rockall score | 5.4 (3.8, 7.0) | 5.3 (3.5, 7.1) |
Numerical variables expressed as mean with 95% confidence interval of distribution. No statistically significant difference between the two groups. OME, omeprazole; RAB, rabeprazole; NBVV, nonbleeding visible vessels.